vs
Pennant Group, Inc.（PNTG）与Strata Critical Medical, Inc.（SRTA）财务数据对比。点击上方公司名可切换其他公司
Pennant Group, Inc.的季度营收约是Strata Critical Medical, Inc.的12.7倍（$289.3M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 53.2%）。Pennant Group, Inc.自由现金流更多（$17.4M vs $-10.2M）。过去两年Pennant Group, Inc.的营收复合增速更高（35.8% vs -33.6%）
Pennant Group, Inc.是一家总部位于美国的医疗服务企业，主营家庭健康护理、临终关怀、长者居住服务及专业护理服务，业务覆盖美国数十个州，核心服务对象为老年及有特殊医疗需求的弱势人群。
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
PNTG vs SRTA — 直观对比
营收规模更大
PNTG
是对方的12.7倍
$22.7M
营收增速更快
SRTA
高出308.0%
53.2%
自由现金流更多
PNTG
多$27.6M
$-10.2M
两年增速更快
PNTG
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $289.3M | $22.7M |
| 净利润 | $8.6M | — |
| 毛利率 | — | -0.9% |
| 营业利润率 | 6.0% | -18.4% |
| 净利率 | 3.0% | — |
| 营收同比 | 53.2% | 361.2% |
| 净利润同比 | 50.0% | — |
| 每股收益（稀释后） | $0.25 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PNTGSRTA
| Q4 25 | $289.3M | $22.7M | ||
| Q3 25 | $229.0M | $49.3M | ||
| Q2 25 | $219.5M | $70.8M | ||
| Q1 25 | $209.8M | $54.3M | ||
| Q4 24 | $188.9M | $-8.7M | ||
| Q3 24 | $180.7M | $36.1M | ||
| Q2 24 | $168.7M | $67.9M | ||
| Q1 24 | $156.9M | $51.5M |
净利润PNTGSRTA
| Q4 25 | $8.6M | — | ||
| Q3 25 | $6.1M | $57.4M | ||
| Q2 25 | $7.1M | $-3.7M | ||
| Q1 25 | $7.8M | $-3.5M | ||
| Q4 24 | $5.8M | — | ||
| Q3 24 | $6.2M | $-2.0M | ||
| Q2 24 | $5.7M | $-11.3M | ||
| Q1 24 | $4.9M | $-4.2M |
毛利率PNTGSRTA
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
营业利润率PNTGSRTA
| Q4 25 | 6.0% | -18.4% | ||
| Q3 25 | 4.5% | -11.4% | ||
| Q2 25 | 5.3% | -7.0% | ||
| Q1 25 | 6.0% | -14.0% | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 6.0% | -19.7% | ||
| Q2 24 | 5.7% | -17.9% | ||
| Q1 24 | 5.4% | -19.2% |
净利率PNTGSRTA
| Q4 25 | 3.0% | — | ||
| Q3 25 | 2.7% | 116.5% | ||
| Q2 25 | 3.2% | -5.3% | ||
| Q1 25 | 3.7% | -6.4% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 3.4% | -5.4% | ||
| Q2 24 | 3.4% | -16.7% | ||
| Q1 24 | 3.1% | -8.2% |
每股收益（稀释后）PNTGSRTA
| Q4 25 | $0.25 | $-0.11 | ||
| Q3 25 | $0.17 | $0.70 | ||
| Q2 25 | $0.20 | $-0.05 | ||
| Q1 25 | $0.22 | $-0.04 | ||
| Q4 24 | $0.16 | $-0.11 | ||
| Q3 24 | $0.20 | $-0.03 | ||
| Q2 24 | $0.18 | $-0.15 | ||
| Q1 24 | $0.16 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $31.0M |
| 总债务越低越好 | $168.8M | — |
| 股东权益账面价值 | $374.3M | $279.1M |
| 总资产 | $968.2M | $325.5M |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资PNTGSRTA
| Q4 25 | — | $31.0M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | — | $58.8M | ||
| Q1 25 | — | $34.8M | ||
| Q4 24 | — | $18.4M | ||
| Q3 24 | — | $20.0M | ||
| Q2 24 | — | $26.3M | ||
| Q1 24 | — | $36.8M |
总债务PNTGSRTA
| Q4 25 | $168.8M | — | ||
| Q3 25 | $26.0M | — | ||
| Q2 25 | $37.0M | — | ||
| Q1 25 | $52.5M | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $108.9M | — | ||
| Q2 24 | $82.2M | — | ||
| Q1 24 | $83.3M | — |
股东权益PNTGSRTA
| Q4 25 | $374.3M | $279.1M | ||
| Q3 25 | $343.0M | $283.0M | ||
| Q2 25 | $333.6M | $223.1M | ||
| Q1 25 | $323.0M | $219.7M | ||
| Q4 24 | $312.0M | $221.9M | ||
| Q3 24 | $187.3M | $233.5M | ||
| Q2 24 | $173.0M | $229.4M | ||
| Q1 24 | $164.2M | $236.6M |
总资产PNTGSRTA
| Q4 25 | $968.2M | $325.5M | ||
| Q3 25 | $753.6M | $335.1M | ||
| Q2 25 | $751.4M | $257.9M | ||
| Q1 25 | $743.6M | $250.6M | ||
| Q4 24 | $679.5M | $256.7M | ||
| Q3 24 | $646.8M | $282.9M | ||
| Q2 24 | $602.5M | $280.3M | ||
| Q1 24 | $578.2M | $282.8M |
负债/权益比PNTGSRTA
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 0.11× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.0M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | $17.4M | $-10.2M |
| 自由现金流率自由现金流/营收 | 6.0% | -44.7% |
| 资本支出强度资本支出/营收 | 1.2% | 8.1% |
| 现金转化率经营现金流/净利润 | 2.43× | — |
| 过去12个月自由现金流最近4个季度 | $36.3M | $-58.5M |
8季度趋势，按日历期对齐
经营现金流PNTGSRTA
| Q4 25 | $21.0M | $-8.3M | ||
| Q3 25 | $13.9M | $-37.3M | ||
| Q2 25 | $34.6M | $-3.1M | ||
| Q1 25 | $-21.2M | $-246.0K | ||
| Q4 24 | $20.6M | $-1.8M | ||
| Q3 24 | $7.7M | $6.4M | ||
| Q2 24 | $10.5M | $8.4M | ||
| Q1 24 | $545.0K | $-15.6M |
自由现金流PNTGSRTA
| Q4 25 | $17.4M | $-10.2M | ||
| Q3 25 | $10.5M | $-40.1M | ||
| Q2 25 | $31.6M | $-5.4M | ||
| Q1 25 | $-23.2M | $-2.9M | ||
| Q4 24 | $17.2M | $-6.3M | ||
| Q3 24 | $6.8M | $-3.0M | ||
| Q2 24 | $8.9M | $-7.7M | ||
| Q1 24 | $-2.6M | $-16.4M |
自由现金流率PNTGSRTA
| Q4 25 | 6.0% | -44.7% | ||
| Q3 25 | 4.6% | -81.4% | ||
| Q2 25 | 14.4% | -7.6% | ||
| Q1 25 | -11.1% | -5.3% | ||
| Q4 24 | 9.1% | 72.7% | ||
| Q3 24 | 3.8% | -8.2% | ||
| Q2 24 | 5.3% | -11.4% | ||
| Q1 24 | -1.7% | -31.8% |
资本支出强度PNTGSRTA
| Q4 25 | 1.2% | 8.1% | ||
| Q3 25 | 1.5% | 5.7% | ||
| Q2 25 | 1.4% | 3.2% | ||
| Q1 25 | 0.9% | 4.8% | ||
| Q4 24 | 1.8% | -52.6% | ||
| Q3 24 | 0.5% | 25.8% | ||
| Q2 24 | 1.0% | 23.8% | ||
| Q1 24 | 2.0% | 1.6% |
现金转化率PNTGSRTA
| Q4 25 | 2.43× | — | ||
| Q3 25 | 2.29× | -0.65× | ||
| Q2 25 | 4.89× | — | ||
| Q1 25 | -2.73× | — | ||
| Q4 24 | 3.57× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.84× | — | ||
| Q1 24 | 0.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PNTG
| Home Health Subsegment | $136.2M | 47% |
| Hospice Subsegment | $97.1M | 34% |
| Private And Other | $36.4M | 13% |
| Medicare And Medicaid | $19.6M | 7% |
| Affiliated Entity | $2.2M | 1% |
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
